Literature DB >> 29344136

Clinical outcome of extended-field irradiation vs. pelvic irradiation using intensity-modulated radiotherapy for cervical cancer.

Yi Ouyang1, Yanhong Wang2, Kai Chen1, Xinping Cao1, Yiming Zeng3.   

Abstract

The aim of the present study was to evaluate the distinctions in survival and toxicity between patients with cervical cancer with common iliac node or para-aortic node involvement, who were treated with extended-field intensity-modulated radiotherapy (EF-IMRT) and patients with or without lower involved pelvic nodes, who were treated with pelvic IMRT. A total of 55 patients treated with EF-IMRT and 52 patients treated with pelvic IMRT at the Sun Yat-Sen University Cancer Center (Guangzhou, China) were retrospectively analyzed. Patients treated with EF-IMRT had the highest level of lymph node involvement to the para-aortic or common iliac nodes, while patients treated with pelvic IMRT had no para-aortic or common iliac nodes involved (P<0.001). The median follow-up time was 29.5 months. The 3-year overall survival (OS) rates of EF-IMRT and pelvic IMRT were 79.4 and 82.3% (P=0.45), respectively, and the 3-year disease-free survival (DFS) rates of EF-IMRT and pelvic IMRT were 61.0 and 73.7% (P=0.55), respectively. Cox's regression analysis revealed that EF irradiation was a protective prognostic factor for OS and DFS. A total of 16 patients in the EF-IMRT group and 13 patients in the pelvic IMRT group experienced treatment failure (P=0.67), with the patterns of failure being the same for the two groups (P=0.88). The cumulative incidence of grade 3 and 4 acute toxicities in the EF-IMRT group was 34.5%, in comparison with 19.2% in the pelvic group (P=0.048). The results of the present study suggest that patients with cervical cancer with grossly involved common iliac or para-aortic nodes should be electively subjected to EF irradiation to improve the survival and alter patterns of recurrence. Notably, EF irradiation delivered via IMRT exhibits an increased toxicity incidence, however, this remains within an acceptable range.

Entities:  

Keywords:  cervical cancer; extended-field radiotherapy; intensity-modulated radiotherapy; pelvic radiotherapy; survival; toxicity

Year:  2017        PMID: 29344136      PMCID: PMC5754842          DOI: 10.3892/ol.2017.7077

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  20 in total

1.  Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer.

Authors:  Karen Lim; William Small; Lorraine Portelance; Carien Creutzberg; Ina M Jürgenliemk-Schulz; Arno Mundt; Loren K Mell; Nina Mayr; Akila Viswanathan; Anuja Jhingran; Beth Erickson; Jennifer De los Santos; David Gaffney; Catheryn Yashar; Sushil Beriwal; Aaron Wolfson; Alexandra Taylor; Walter Bosch; Issam El Naqa; Anthony Fyles
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-14       Impact factor: 7.038

2.  Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies.

Authors:  Joseph K Salama; Arno J Mundt; John Roeske; Neil Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-26       Impact factor: 7.038

3.  FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.

Authors: 
Journal:  Int J Gynaecol Obstet       Date:  2014-02-22       Impact factor: 3.561

4.  Lymph node staging by positron emission tomography in patients with carcinoma of the cervix.

Authors:  P W Grigsby; B A Siegel; F Dehdashti
Journal:  J Clin Oncol       Date:  2001-09-01       Impact factor: 44.544

5.  Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.

Authors:  Elizabeth A Kidd; Barry A Siegel; Farrokh Dehdashti; Janet S Rader; David G Mutch; Matthew A Powell; Perry W Grigsby
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

6.  Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20.

Authors:  M Rotman; T F Pajak; K Choi; M Clery; V Marcial; P W Grigsby; J Cooper; M John
Journal:  JAMA       Date:  1995-08-02       Impact factor: 56.272

7.  Are Radiation Therapy Oncology Group Para-aortic Contouring Guidelines for Pancreatic Neoplasm applicable to other malignancies--assessment of nodal distribution in gynecological malignancies.

Authors:  Peyman Kabolizadeh; Suyash Fulay; Sushil Beriwal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-07-09       Impact factor: 7.038

8.  Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis.

Authors:  Hong In Yoon; Jihye Cha; Ki Chang Keum; Ha Yoon Lee; Eun Ji Nam; Sang Wun Kim; Sunghoon Kim; Young Tae Kim; Gwi Eon Kim; Yong Bae Kim
Journal:  Radiat Oncol       Date:  2015-01-13       Impact factor: 3.481

9.  Surgical staging of para-aortic LN in patients with locally advanced cervix cancer and no evidence of metastases in preoperative PET/CT imaging.

Authors:  Ming Yin Lin; Thomas W Jobling; Kailash Narayan
Journal:  J Gynecol Oncol       Date:  2015-09-23       Impact factor: 4.401

10.  Prognostic factors associated with radiotherapy for cervical cancer with computed tomography-detected para-aortic lymph node metastasis.

Authors:  Szu-Yuan Wu; Eng-Yen Huang; Chan-Chao Chanchien; Hao Lin; Chong-Jong Wang; Li-Min Sun; Hui-Chun Chen; Fu-Min Fang; Hsuan-Chih Hsu; Yu-Jie Huang
Journal:  J Radiat Res       Date:  2013-06-27       Impact factor: 2.724

View more
  4 in total

Review 1.  The impact of para-aortic lymph node irradiation on disease-free survival in patients with cervical cancer: A systematic review and meta-analysis.

Authors:  Leslie J H Bukkems; Ina M Jürgenliemk-Schulz; Femke van der Leij; Max Peters; Cornelis G Gerestein; Ronald P Zweemer; Peter S N van Rossum
Journal:  Clin Transl Radiat Oncol       Date:  2022-05-30

2.  Clinical Observation of Prophylactic Extended-Field Intensity-Modulated Radiation Therapy with Synchronous Chemotherapy in Locally Advanced Cervical Cancer.

Authors:  Xue Huang; Mingming Fang; Lin Zhu; Cheng Gu; Han Cui; Chun Yang; Yuxing Yang
Journal:  Med Sci Monit       Date:  2021-09-07

Review 3.  Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review.

Authors:  Fengying Qin; Huiting Pang; Tao Yu; Yahong Luo; Yue Dong
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

4.  Cervical cancer patient reported gastrointestinal outcomes: intensity/volumetric modulated vs. 3D conformal radiation therapy.

Authors:  Ryan Urban; Justin Wong; Peter Lim; Susan Zhang; Ingrid Spadinger; Robert Olson; Francois Bachand; Clement Ho; Anna V Tinker; Lovedeep Gondara; Sarah Nicole Hamilton
Journal:  J Gynecol Oncol       Date:  2022-07-07       Impact factor: 4.756

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.